Background
==========

Hairy/enhancer of split 3 (*Hes3*) is a basic helix-loop-helix (bHLH) gene mapped to human chromosome 1p36.31 [@B1], [@B2]. The proteins of Hes family have similarities and also differences in their structures and functions [@B3]. The full length of Hes3 has a particular type of basic domain that binds to the N-box (CACNAG) [@B4]. Unlike other members of the family, Hes3 lacks a domain that combines with the E-box. However, it can affect gene transcription by indirectly interacting with the E-box [@B3]. Hes3 was found to play important roles in neural cell differentiation [@B2], [@B3]. Hiromi\'s study [@B2] indicated that concurrent *Hes3* and *Hes1* mutations led to abnormal brain development in mice. Hes3 was also found to have roles in promoting self-renewal of neural stem cells [@B5]. In the process, Hes3 transcription was upregulated by a phosphorylated form of STAT3-Ser in a non-canonical Notch pathway [@B5]. However, the functioning of Hes3 is not clear yet. As STAT3-Ser was revealed to play important roles in regulating tumor proliferation, Hes3 was presumed to be involved in regulation of cancer proliferation. Jimmy\'s study [@B6] showed that Hes3 expression in pancreatic islet MIN6 cells was stimulated under serum-free conditions. Deric\'s study [@B7] indicated that Hes3 may be an important regulator of stem cell numbers in glioblastoma multiforme. However, the expression and function of Hes3 in human cancers is largely unknown. In the current study, we investigated the expression of Hes3 in healthy human lung and non-small cell lung cancer (NSCLC) tissues, its function, and the possible molecular mechanism in cancer cells *in vitro*.

Materials and Methods
=====================

Tissue samples
--------------

Lung and NSCLC tissue samples were obtained from patients at the First Affiliated Hospital of China Medical University. The tumors were diagnosed according to the criteria for classification of lung cancer published by the World Health Organization [@B8]. There were 45 cases of squamous cell carcinomas (SCCs) and 67 cases of adenocarcinomas. This study was approved by the Institutional Review Board of China Medical University. Informed consent was obtained from all enrolled patients.

Immunohistochemistry
--------------------

Immunohistochemistry staining was performed using SP-kit according to the manufacturer\'s instructions and as described previously [@B9]. The primary antibody against Hes3 was purchased from Santa Cruz (USA). The evaluation of Hes3 immunostaining was performed as described previously [@B9]. Evaluation of IHC staining was based on two parameters: the proportion of immunopositive cells and the intensity. The proportion of positive cells was categorized as follows: 0: \<10%; 1: ≥10% to \<25%; 2: ≥25% to \<50%; 3: ≥50% to \<75% and 4: ≥75%. The immunostaining intensity was categorized as follows: 0: no positivity; 1: weak (pale yellow, without obvious grains); 2: moderate (pale brown, with small grains) and 3: strong (dark brown, with obvious large grains). A final immunoreactivity score was calculated by multiplying the two individual scores. A final score less than 2 was considered as negative. Scores of 2 or more were considered as positive.

Western blotting
----------------

Western blotting was performed as described previously [@B9]. Primary antibody against Hes3 (sc-55587, Santa Cruz, USA, dilution 1:200), MMP7 (\#71031, Cell signaling, USA, dilution 1:500), Cyclin D1 (sc-4074, Santa Cruz, USA, dilution 1:200), Cyclin D3 (sc-135875, Santa Cruz, USA, dilution 1:200), and GADPH (ab8245, Abcam, HK; 1:1000) were purchased.

Cell culture and transfection
-----------------------------

Human bronchial epithelial cell (HBE) and carcinoma cell AGZY-83a, H292, A549, LK2, NCI-H1299, LTE, and NCI-H460 were cultured in RPMI 1640 tissue culture medium (Invitrogen, Carlsbad, CA, USA), containing 10% fetal calf serum (Invitrogen), 100 IU/mL penicillin (Sigma, St Louis, MO, USA), and 100 μg/mL streptomycin (Sigma) at 37 °C in a humidified atmosphere (5% CO~2~). Hes3 cDNA clone was purchased from Origene (USA). Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was used for transient transfection according to the manufacturer\'s instructions and as described previously [@B9].

MTT assay
---------

MTT assay was performed as described previously [@B10].

Matrigel invasion assay
-----------------------

24-well Transwell with 8-μm pore polycarbonate membrane inserts (Corning, NY, USA) and matrigel (BD Bioscience) was used to examine the invasive ability of cancer cells according to the manufacturer\'s instructions and as described previously [@B9].

Statistical analysis
--------------------

We used SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) to analyze the data. Pearson\'s chi-squared test was used to analyze the association between Hes3 expression and the clinicopathological features. McNemar\'s test was used for comparison of Hes3 expression in healthy and cancerous lung tissues. All data of the *in vitro* study is expressed as mean ± standard deviation (S.D.) and the experiment was repeated at least 3 times. *p*-values of \< 0.05 were considered significant.

Results
=======

Expression of Hes3 in healthy human lung and NSCLC tissues
----------------------------------------------------------

We used immunohistochemistry to detect Hes3 expression in NSCLC and paired normal lung tissues. Hes3 expression was detected in cytoplasm and nucleus of normal and cancer epithelial cells (Figure [1](#F1){ref-type="fig"}). Hes3 immunostaining in bronchial epithelial cells and epithelial cells of submucosal glands was generally weak and the total positive rate was of 30.3% (10/33). Hes3 expression in NSCLC tissues including squamous cell carcinoma and adenocarcinoma was higher than that in the normal lung tissues (p \< 0.05). The total positive rate of Hes3 in cancer tissues was 51.8% (58/112).

Clinicopathological significance of Hes3 expression in NSCLC
------------------------------------------------------------

The association of Hes3 in NSCLC and the clinicopathological features is shown in Table [1](#T1){ref-type="table"}. Hes3 expression was significantly associated with poor differentiation and advanced TNM stages (III + IV versus I + II) (p \< 0.05). Hes3 expression in cancer tissues was also related with lymph node metastasis (*p* \< 0.05). Survival time analysis revealed that the patients with Hes3 expression had shorter survival time (33.8 ± 6.4 m) than those without Hes3 expression (50.9 ± 6.8 m) (*p* \< 0.05) (Figure [2](#F2){ref-type="fig"}).

Hes3 regulated cell proliferation and invasion in HBE, A549 and LK2 cells *in vitro*
------------------------------------------------------------------------------------

First, we examined the expression of Hes3 in HBE cells and carcinoma cells AGZY-83a, H292, A549, LK2, NCI-H1299, LTE, and NCI-H460 using western blotting. The results showed that Hes3 was expressed in all these cells in variable levels (Figure [3](#F3){ref-type="fig"}). Hes3 expression in HBE cells was relatively lower than that in lung cancer cells including H292, LK2, and NCI-H460 (p \< 0.05). We selected A549 cells and HBE cells with lower Hes3 expression to investigate the function of Hes3 in epithelial and cancer cells. We transfected Hes3 cDNA in HBE and A549 cells to overexpress Hes3. MTT assay showed that overexpression of Hes3 in HBE and A549 cells significantly upregulated proliferation (Figure [4](#F4){ref-type="fig"}) (p \< 0.05). Transwell study showed that upregulation of Hes3 in HBE and A549 cells significantly promoted the ability of cells to invade (Figure [5](#F5){ref-type="fig"}) (p \< 0.05). We using transfection of Hes3 shRNA to inhibit Hes3 expression in LK2 cells. MTT assay showed that downregulation of Hes3 in LK2 cells significantly inhibited proliferation (figure [4](#F4){ref-type="fig"}) (p\<0.05). Transwell study showed that downregulation of Hes3 expression in LK2 cells significantly inhibited the ability of invasion of cancer cells (figure [5](#F5){ref-type="fig"}) (p\<0.05).

Hes3 regulated Cyclin D1, Cyclin D3 and MMP7 expression in HBE, A549 and LK2 cells
----------------------------------------------------------------------------------

Next, we investigated the possible molecular mechanism underlying the function of Hes3 to promote cancer cell proliferation and invasion. Western blotting study showed that overexpression of Hes3 in HBE and A549 cells after transfection of Hes3 cDNA significantly upregulated the expression of Cyclin D1, Cyclin D3, and MMP7 (*p* \< 0.05), while inhibition of Hes3 expression in LK2 cells significantly downregulated expression of Cyclin D1, Cyclin D3 and MMP7 (p\<0.05) (figure [6](#F6){ref-type="fig"} A, B).

Discussion
==========

Currently, the research on the role of Hes3 is mainly focused on finding whether it is regulatory in certain special processes, but not on its effect on these processes. Corrinne\'s study [@B3] indicated that Hes3 played important roles in development of brain in the embryo. Hirata\'s research [@B2] showed that a mutation in *Hes3* gene led to abnormal development of the brain in mice. Hes3 was also considered as a marker of neural endogenous putative progenitor cells of the brain [@B11]. It was found to be involved in the regulation of neural cell differentiation [@B11]. Hes3 expression was also found to be regulated during the process of demyelination and remyelination [@B12].

*Hes3* was found to be a non-canonical Notch target gene [@B13]. In this signaling pathway, STAT3 gets phosphorylated at the ser site and leads to the transcription of *Hes3* [@B5]. Hence, the pathway was also termed as STAT3-Hes3 signaling pathway, which was found to be involved in the regulation of neural cell differentiation [@B5], [@B14]. Transcription of *Hes3* is regulated by STAT3 to decide the timing of neural cell differentiation [@B11], but the functioning of Hes3 is not clear yet.

There are few reports of Hes3 expression in healthy human tissues at present. Katoh\'s [@B15] integrative genomic analyses indicated expression of Hes3 in embryonic stem cells. Economopoulou [@B16] found that Hes3 expression was detected in human eye and pterygium, which indicated a possible function of STAT3-Hes3 signaling in these tissues. However, the exact function was unknown. In our current study, we found that Hes3 was also detected in healthy human lung tissues, though the immunostaining showed that its levels were generally low. On the contrary, we found that Hes3 was overexpressed in NSCLC tissues compared to healthy lung tissues. Moreover, the clinicopathological analysis showed that Hes3 may contribute to cancer development and poor clinical outcome. We also demonstrated that overexpression of Hes3 in A549 cells promoted cancer cell proliferation and invasion *in vitro*. Some studies have indicated a link between Hes3 and cell proliferation [@B6], [@B7], [@B17], [@B18]. Masjkur\'s study [@B6] showed that Hes3 may be an important regulator of growth of pancreatic islet cells and may affect insulin release. Their research showed that Hes3 can affect the number of specific cell groups in glioblastoma multiforme, namely the stem cells [@B7]. These studies mainly found that Hes3 was upregulated in these processes, but the functioning of Hes3 and the related molecular targets was not clear. In our study, we found that Hes3 could regulate the expression of Cyclin D1 and Cyclin D3, two novel Cyclins, which indicates that Hes3 may promote cancer cell proliferation through the regulation of cell cycle. Masjkur\'s study indicates that Hes3 regulates cell growth and gene expression including Golph3 in the adult pancreatic islet [@B6]. Wu\'s study proved that GOLPH3 promotes glioma progression through regulating Cyclin D1 and c-myc [@B19]. These studies may indicate a possible link between Hes3 and Cyclin Ds. However, the mechanism behind the regulation of these Cyclins needs to be further studied. Many proteins of the Matrix metalloproteinase (MMP) family have been found to be extracellular matrix remodeling endopeptidases involved in cancer invasion and metastasis [@B19]. We found in this study that MMP7, a member of this family, was upregulated by Hes3 in A549 cancer cells, which indicates that Hes3 may promote cancer cell invasion through the regulation of MMP7. Wang\'s study showed that GOLPH3 promotes Wnt/β‑catenin signal activation [@B21], which may indicate a possible link between Hes3 and MMP7, a downstream molecule of Wnt/β‑catenin signal. However, the detailed pathway is not clear yet.

Conclusion
==========

Hes3 expression in human carcinomas was largely unknown. In the current study, we found that Hes3 was overexpressed in NSCLC compared to healthy lung tissues. Hes3 expression was significantly associated with cancer development. *In vitro* study showed that Hes3 could promote cancer cell proliferation and invasion, possibly through the regulation of Cyclin D1, Cyclin D3, and MMP7. These results indicated that Hes3 may be a promising cancer marker in NSCLC.
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![**Expression of Hes3 in healthy lung and NSCLC tissues.** (A) Negative (white arrow) and (B) weak expression (black arrow) of Hes3 in bronchial epithelial cells. (C) Negative (white arrow) and (D) weak expression (black arrow) of Hes3 in epithelial cells of the submucosal glands. Strong and diffused Hes3 expression was detected in cytoplasm and nuclei of cancer cells of (E) squamous cell carcinoma (white arrow) and (F) adenocarcinoma (black arrow) . (A, B, C, and D, 100X; E and F, 400X).](ijmsv16p0470g001){#F1}

![**Survival analysis.** The overall Kaplan-Meier survival curves demonstrated that the survival time of patients with Hes3 expression in NSCLC (33.8 ± 6.4 m) was significantly shorter than in those without Hes3 expression (50.9 ± 6.8 m) (Log rank analysis, *p* \< 0.05).](ijmsv16p0470g002){#F2}

![**Expression of Hes3 in cell lines *in vitro*.** Hes3 expression was detected using western blotting in HBE and carcinoma cells AGZY-83a, H292, A549, LK2, NCI-H1299, LTE, and NCI-H460. Hes3 expression levels in H292, LK2, and H460 cells were significantly higher than those in HBE cells (\*, *p* \< 0.05).](ijmsv16p0470g003){#F3}

![**Regulation of cancer cell proliferation by Hes3.** MTT study showed that overexpression of Hes3 in HBE and A549 cells significantly upregulated cancer cell proliferation and inhibition of Hes3 expression in LK2 cells significantly downregulated cancer cell proliferation (*p* \< 0.05).](ijmsv16p0470g004){#F4}

![**Regulation of cancer cell invasion by Hes3.** Transwell study demonstrated that overexpression of Hes3 in HBE and A549 cells significantly upregulated cancer cell invasion and inhibition of Hes3 expression in LK2 cells significantly downregulated cancer cell invasion (\*, *p* \< 0.05).](ijmsv16p0470g005){#F5}

![**Molecular mechanism behind the regulation by Hes3.** Western blotting study showed that overexpression of Hes3 in HBE and A549 cells significantly upregulated Cyclin D1, Cyclin D3, and MMP7, while inhibition of Hes3 expression in LK2 cells significantly downregulated Cyclin D1, Cyclin D3, and MMP7 (\*, *p* \< 0.05)](ijmsv16p0470g006){#F6}

###### 

Distribution of Hes3 status in non-small cell lung cancer according to clinicopathological features

  Characteristics             Numbers of patients   Hes3 immunostaining   *p*^\*^   
  --------------------------- --------------------- --------------------- --------- --------------
  **Total**                   112                   54                    58        
  **Age(y)**                                                                        
  \<55                        27                    14                    13        0.664
  ≥55                         85                    40                    45        
  **Gender**                                                                        
  male                        66                    29                    37        0.278
  female                      46                    25                    21        
  **Histological type**                                                             
  squamous cell carcinoma     45                    21                    24        0.788
  adenocarcinoma              67                    33                    34        
  **Grade**                                                                         
  well                        23                    16                    7         [0.000]{.ul}
  Moderate and poor           89                    38                    51        
  **TNM stage**                                                                     
  Ⅰ and Ⅱ                     70                    45                    25        [0.000]{.ul}
  Ⅲ and Ⅳ                     42                    9                     33        
  **Lymph node metastasis**                                                         
  No                          65                    39                    26        [0.003]{.ul}
  Yes                         47                    15                    32        

\* *p* values were obtained with the X^2^ test.

[^1]: Competing Interests: The authors have declared that no competing interest exists.
